Plasma FGF23 and the risk of stroke: The Northern Manhattan Study (NOMAS)

Neurology

Volumn 82, Issue 19, 2014, Pages 1700-1706

  Wright, Clinton B ^a,b   Dong, Chuanhui ^a,b   Stark, Matthew ^b   Silverberg, Shonni ^c   Rundek, Tatjana ^a,b   Elkind, Mitchell S V ^c,d   Sacco, Ralph L ^a,b   Mendez, Armando ^b   Wolf, Myles ^b  

^a UNIVERSITY OF MIAMI   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c Department of Public Health Sciences University of Miami ^*  (United States)

^d Department of Human Genomics University of Miami ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 23; PARATHYROID HORMONE; PHOSPHATE;

AGED; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPOTHESIS; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PRIORITY JOURNAL; RACE DIFFERENCE; RISK FACTOR; URBAN AREA; URBAN POPULATION;

AGED; CEREBRAL HEMORRHAGE; FEMALE; FIBROBLAST GROWTH FACTORS; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; NEW YORK CITY; PARATHYROID HORMONE; PHOSPHATES; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS; STROKE; URBAN POPULATION;

EID: 84902142347     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0000000000000410     Document Type: Article

References (28)

1. Gutierrez OM, Mannstadt M, Isakova T, et al. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med 2008;359:584-592.
2. Isakova T, Xie H, Yang W, et al. Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011;305:2432-2439.
3. Ix JH, Katz R, Kestenbaum BR, et al. Fibroblast growth factor-23 and death, heart failure, and cardiovascular events in community-living individuals: CHS (Cardiovascular Health Study). J Am Coll Cardiol 2012;60:200-207.
4. Schoppet M, Hofbauer LC, Brinskelle-Schmal N, et al. Serum level of the phosphaturic factor FGF23 is associated with abdominal aortic calcification in men: the STRAMBO Study. J Clin Endocrinol Metab 2012;97:E575-E583.
5. Lim K, Lu TS, Molostvov G, et al. Vascular Klotho deficiency potentiates the development of human artery calcification and mediates resistance to fibroblast growth factor Circulation 2012;125:2243-2255.
6. Gutierrez OM, Januzzi JL, Isakova T, et al. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation 2009;119:2545-2552.
7. Faul C, Amaral AP, Oskouei B, et al. FGF23 induces left ventricular hypertrophy. J Clin Invest 2011;121:4393-4408.
8. Ärnlöv J, Carlsson AC, Sundström J, et al. Serum FGF23 and risk of cardiovascular events in relation to mineral metabolism and cardiovascular pathology. Clin J Am Soc Nephrol 2013;8:781-786.
9. Arnlov J, Carlsson AC, Sundstrom J, et al. Higher fibroblast growth factor-23 increases the risk of all-cause and cardiovascular mortality in the community. Kidney Int 2013;83:160-166.
10. Parker BD, Schurgers LJ, Brandenburg VM, et al. The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med 2010; 152:640-648.
11. Sacco RL, Boden-Albala B, Gan R, et al. Stroke incidence among white, black, and Hispanic residents of an urban community: the Northern Manhattan Stroke Study. Am J Epidemiol 1998;147:259-268.
12. Sacco RL, Boden-Albala B, Abel G, et al. Race-ethnic disparities in the impact of stroke risk factors: the Northern Manhattan Stroke Study. Stroke 2001;32:1725-1731.
13. Wallman KK, Hodgdon J. Race and ethnic standards for federal statistics and administrative reporting. Stat Rep 1977;77-110:450-454.
14. Gentry EM, Kalsbeek WD, Hogelin GC, et al. The behavioral risk factor surveys: II: design, methods, and estimates from combined state data. Am J Prev Med 1985;1:9-14.
15. Boden-Albala B, Cammack S, Chong J, et al. Diabetes, fasting glucose levels, and risk of ischemic stroke and vascular events: findings from the Northern Manhattan Study (NOMAS). Diabetes Care 2008;31:1132-1137.
16. Levey A, Kusek J, Beck G. A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 2000;11:155A. Abstract.
17. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009;150:604-612.
18. Inker LA, Schmid CH, Tighiouart H, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 2012;367:20-29.
19. Yilmaz MI, Sonmez A, Saglam M, et al. Longitudinal analysis of vascular function and biomarkers of metabolic bone disorders before and after renal transplantation. Am J Nephrol 2013;37:126-134.
20. Desjardins L, Liabeuf S, Renard C, et al. FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages. Osteoporos Int 2012;23:2017-2025.
21. Nakayama M, Kaizu Y, Nagata M, et al. Fibroblast growth factor 23 is associated with carotid artery calcification in chronic kidney disease patients not undergoing dialysis: a cross-sectional study. BMC Nephrol 2013;14:22.
22. Mirza MA, Larsson A, Melhus H, Lind L, Larsson TE. Serum intact FGF23 associate with left ventricular mass, hypertrophy and geometry in an elderly population. Atherosclerosis 2009;207:546-551.
23. van Ballegooijen AJ, Visser M, Cotch MF, et al. Serum vitamin D and parathyroid hormone in relation to cardiac structure and function: the ICELAND-MI substudy of AGESReykjavik. J Clin Endocrinol Metab 2013;98:2544-2552.
24. Piovesan A, Molineri N, Casasso F, et al. Left ventricular hypertrophy in primary hyperparathyroidism: effects of successful parathyroidectomy. Clin Endocrinol 1999;50:321-328.
25. Wermers RA, Khosla S, Atkinson EJ, et al. Incidence of primary hyperparathyroidism in Rochester, Minnesota, 1993-2001: an update on the changing epidemiology of the disease. J Bone Miner Res 2006;21:171-177.
26. Isakova T, Xie H, Barchi-Chung A, et al. Daily variability in mineral metabolites in CKD and effects of dietary calcium and calcitriol. Clin J Am Soc Nephrol 2012;7:820-828.
27. Brondum-Jacobsen P, Nordestgaard BG, Schnohr P, Benn M. 25-Hydroxyvitamin D and symptomatic ischemic stroke: an original study and meta-analysis. Ann Neurol 2013;73:38-47.
28. Hasegawa H, Nagano N, Urakawa I, et al. Direct evidence for a causative role of FGF23 in the abnormal renal phosphate handling and vitamin D metabolism in rats with early-stage chronic kidney disease. Kidney Int 2010;78:975-980.